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Abstract
In this paper we develop a new mathematical model of immunotherapy and cancer vaccination,
focusing on the role of antigen presentation and costimulatory signaling pathways in cancer immunology.
We investigate the effect of different cancer vaccination protocols on the well-documented phenomena of
cancer dormancy and recurrence, and we provide a possible explanation of why adoptive immunotherapy
protocols can sometimes promote tumor growth instead of inhibiting it (a phenomenon called immunos-
timulation), as opposed to active vaccination protocols based on tumor-antigen pulsed dendritic cells.
Significantly, our simulations suggest that elevated numbers of professional antigen presenting cells
correlate well with prolonged time periods of cancer dormancy.
1 Introduction
Cancer still remains one of the most difficult diseases
to treat clinically and is one of the main causes of
mortality in developed western societies. The mor-
tality statistics for the United Kingdom for the year
2005 show that 153,491 people were registered as
dying from a malignant neoplasm.1 This figure rep-
resents 26% of all causes of death in the UK for 2005,
and similar statistics hold for the United States (Ries
et al., 2007).
Great effort and resources are devoted to cancer
research and our understanding of cancer biology
is constantly expanding. However, the overall ef-
ficiency of our current therapeutic approaches re-
mains rather poor. Current patient therapies for
the treatment of cancer include surgery (i.e. re-
moval of the tumour), chemotherapy (administra-
tion of anti-cancer drugs) and radiotherapy (treat-
ment with X-rays). Of course surgery is appropri-
ate only for solid tumours. Although there have
been great advances in patient care and treatment
∗E-mail address: tasos@math.ohio-state.edu
1Source: Cancer Research UK
over the past few decades with refinement of anti-
cancer drugs and medical equipment, unfortunately
chemotherapy and radiotherapy both still carry ma-
jor side-effects for individual patients. This is mainly
due to the severe effects that these treatments have
on normal, healthy proliferating cells in the patients.
As a result, the treatment of cancers itself causes sig-
nificant morbidity and mortality.
Given these facts any design of new therapeutic
approaches is of great interest and one such new ap-
proach is to treat cancer using key components of the
immune system, the body’s natural defence mech-
anism (Abbas et al., 2007). In recent years there
has been much biological, immunological and exper-
imental interest in trying to develop what may be
termed “immunotherapies” for cancers. One major
advantage that some form of effective immunother-
apy treatment would have over conventional anti-
cancer treatment would be the fact that cells and
other components of the immune system would be
far more specific and localised in their actions, tar-
getting cancer cells alone and leaving the vast ma-
jority of other healthy cells of the body untouched
(Parmiani & Lotze, 2002).
1
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As part of a deeper understanding of cancer ther-
apy the role of quantitative and predictive mathe-
matical modelling is becoming increasingly appre-
ciated by experimentalists and clinicians, and in
recent years several papers have begun to investi-
gate the various aspects of the immune system re-
sponse to cancer from a mathematical perspective.
The development of mathematical models which re-
flect several spatial and temporal aspects of tumour
immunology can be regarded as the first step to-
wards an effective computational approach in in-
vestigating the conditions under which tumour re-
currence takes place and in optimizing existing im-
munotherapy protocols. Key papers in this area in-
clude (Ambrosi et al., 2002; Arlotti et al., 2002; De
Angelis et al., 2003; Bellomo et al., 2003; Bellomo
et al., 1999; Bellomo & Preziosi, 2000), which fo-
cus on the modelling of tumour progression and
immune competition by generalized kinetic (Boltz-
mann) models and (Owen & Sherratt, 1997; Owen
& Sherratt, 1998; Owen & Sherratt, 1999; Sherratt
et al., 1999), which focus on the development of tu-
mour heterogeneities as a result of tumour cell and
macrophage interactions. Moreover, Webb et al.
(2002) is concerned with receptor-ligand (Fas-FasL)
dynamics, Kelly et al. (2002) investigate the process
of macrophage infiltration into avascular tumours,
Matzavinos et al. (2004), Matzavinos & Chaplain
(2004) and Chaplain & Matzavinos (2006) focus on
the dynamics of cytotoxic T cell-tumour cell interac-
tions, and finally Forys´ (2002) and Szyman´ska (2003)
analyze various immune system and immunotherapy
models in the context of cancer dynamics.
In this paper we develop a new mathematical
model of immunotherapy, focusing on the role of
antigen presentation and costimulatory signaling
pathways in cancer immunology. We investigate
the effect of different cancer vaccination protocols
on the well-documented phenomena of cancer dor-
mancy and recurrence, and we provide a possible
explanation of why adoptive immunotherapy proto-
cols can sometimes promote tumor growth instead
of inhibiting it2 (Zhang et al., 2007), as opposed to
active vaccination protocols based on tumor-antigen
pulsed dendritic cells (Banchereau & Palucka, 2005).
2A phenomenon that is usually referred to as immunostim-
ulation.
2 The Mathematical Model
2.1 Model formulation
Let us consider a simplified process of a small, grow-
ing, avascular tumour which elicits a response from
the host immune system and attracts a population
of lymphocytes and antigen presenting cells (APCs).
The growing tumour is directly attacked by cyto-
toxic T-lymphocytes (CTLs), which in the presence
of tumour antigens undergo enhanced proliferation.
Antigen presenting cells, such as dendritic cells or
macrophages, internalize tumour cells through either
phagocytosis or endocytosis, and display selected tu-
mour antigenic peptides to the effector cells, i.e. the
CTLs. In the following we only consider the class
I MHC pathway of antigen presentation (Abbas et
al., 2007), where the antigenic peptides are presented
to and activate CTLs directly (as opposed to the
class II MHC pathway that converges to the acti-
vation of helper T-cells that, in turn, activate the
effector components of the host immune system).
The role of antigen presenting cells in the model
is three-fold: (a) they internalize tumour cells and
present tumour antigens to the effector cells, (b) they
kill the internalized tumour cells through the action
of proteolytic enzymes, and (c) they are subjected to
programmed cell death as a result of their present-
ing of antigenic peptides to CTLs. The main effec-
tor functions of this system are performed by CTLs,
which detect antigenic peptides either directly on tu-
mour cells or through the presentation mechanism
implemented by antigen presenting cells. Upon anti-
gen recognition, CTLs bind to the target cell (which
can be either a tumour cell or an antigen presenting
cell with an internalized tumour cell). This binding
event leads to the clustering of a large number of
CTL receptors, trigerring a cascade of events that
converge to the delivery of an apoptotic signal and
the killing of the target cell.
The kinetic interactions between the various cell
types of the model are described by the kinetic
scheme given in Fig. 1. The model consists of
ten time-dependent variables representing the total
numbers of effector cells E, tumour cells T , naive
antigen presenting cells A, tumour cell-loaded APCs
L, CTL-tumour cell complexes CT , CTL-APC com-
plexes CA, CTL-CTL complexes CE , inactivated
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Figure 1: Schematic diagram of the interactions be-
tween effector cells (CTLs), tumour cells and antigen
presenting cells.
CTLs E˜, lethally-hit (or programmed-for-lysis) tu-
mour cells T˜ and programmed-for-lysis loaded APCs
L˜.
The parameters k±T , kCT , kA, kL, k
±
L , kCA , k
±
E and
kCE are non-negative kinetic constants. Parameters
k+T and k
−
T describe the rate of binding of CTLs to
tumour cells and detachment of CTLs from tumour
cells without damaging cells; kCT is the rate of de-
tachment of CTLs from tumour cells, resulting in an
irreversible programming of the tumour cells for lysis
(i.e. death) with probability p or inactivating/killing
CTLs with probability (1−p). Similarly, k±L and k±E
are the corresponding kinetic constants for binding
and detachment of CTLs to tumour cell-loaded anti-
gen presenting cells and other CTLs without dam-
aging cells. Parameters kCA and kCE are the rate
constants for the CTL-mediated killing of (a) loaded
antigen presenting cells and (b) CTLs respectively,
whereas kA and kL characterize the rate of tumour
cell internalization by antigen presenting cells and
the destruction/lysis of internalized tumour cells.
The kinetic step that corresponds to the constant
kCT (1−p) models a direct “counterattack” of the tu-
mour cells against effector immune cells. O’Connell
et al. (1999) have shown that such a mechanism
might be realized through the Fas receptor (Fas,
Apo-1/CD95) and its ligand (FasL, CD95L). En-
gagement of Fas on a target cell by FasL triggers a
cascade of cellular events that result in programmed-
cell-death. Both these transmembrane proteins (be-
longing to the tumour necrosis factor (TNF) fam-
ily of receptors and ligands) are expressed on the
surface of immune cells, including T-lymphocytes
and NK-cells. However, many non-lymphoid tu-
mour cells also express FasL which can counterat-
tack and kill the Fas-sensitive CTLs. On the other
hand, most cancer cells, unlike normal cells, are rel-
atively resistent to Fas-mediated apoptosis by the
immune cells. Resistance to programmed-cell-death
(apoptosis) through the Fas receptor pathway cou-
pled with expression of the Fas ligand might en-
able many cancer cells to deliver a “counterattack”
against attached cytotoxic lymphocytes.
In the formulation of the model, and in addition to
the kinetic mechanisms described in Fig. 1, we con-
sider other kinetic interaction terms accounting for
the host immune system homeostasis, the enhanced
proliferation of lymphocytes in the presence of anti-
gen, etc.
Cytotoxic T-lymphocytes
We assume that there is a source term modelling
the underlying lymphocyte production by the host
immune system, a linear decay (death) term and an
additional CTL proliferation term in response to the
presence of the tumour cells. Combining these as-
sumptions with the kinetics derived from Fig. 1 we
have the following ordinary differential equation for
CTLs:
dE
dt
=
supply︷︸︸︷
s1 −
linear decay︷︸︸︷
d1E +
proliferation︷ ︸︸ ︷
f(CT + CA)
g + T
−
mass action kinetics, according to Fig. 1︷ ︸︸ ︷
k+T ET + (k
−
T + kCT p)CT − k+LLE
+
mass action kinetics︷ ︸︸ ︷
k−LCA + kCACA + 2k
−
ECE
−
Fas/FasL interactions︷ ︸︸ ︷
2k+EE
2 + kCECE , (1)
where s1, d1, f , g, k±E , k
±
T , k
±
L , kCE , kCT , kCA are
all positive constants. The parameter s1 represents
the ‘normal’ rate of flow of mature lymphocytes into
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the tissue (non-enhanced by the presence of tumour
cells).
The proliferation term f(CT + CA)/(g + T ) rep-
resents the experimentally observed enhanced pro-
liferation of CTLs in response to the tumour. Simi-
lar functional forms for this term have been derived
through data fitting and used by Kuznetsov et al.
(1994), Chaplain et al. (1998) and Matzavinos et
al. (2004). This functional form is also consistent
with a model in which one assumes that the en-
hanced proliferation of CTLs is due to signals, such
as released interleukins, generated by effector cells
in target cell-CTL complexes (where a target cell
is either a tumour cell or a antigen presenting cell
with an internalized tumour cell). We note that the
growth factors that are secreted by lymphocytes in
complexes (e.g. IL-2) act mainly in an autocrine
fashion. That is to say they act on the cell from
which they have been secreted. We assume that the
growth factors are produced when lymphocytes are
activated by target cell-CTL interactions. Thus we
define effector cell proliferation to be proportional to
target cell-CTL complex density CT + CA. The ki-
netic interaction terms related to the rate constants
k+E , k
−
E and kCE correspond to Fas/FasL interactions
between effector cells (Marsden & Strasser, 2003).
Tumour cells
The growth dynamics of pre-angiogenic tumours, in
the absence of an immune system response, may be
described adequately by the logistic equation:
dT
dt
= b1T (1− b2T ), (2)
which takes into account a density limitation of
growth (Prigogine & Lefever, 1980; Durand &
Sutherland, 1984). The maximal growth rate of
the tumour cell population is b1, which incorporates
both cell multiplication (mitosis) and death, and the
maximum density of the tumour cells is represented
by the parameter b−12 .
An alternative approach is to modify the logis-
tic growth kinetics by incorporating terms modelling
competition for space between various cell types
(Gatenby, 1995; Gatenby, 1996). However, in the
framework of our model, we will assume that the
CTLs do not compete with the tumour cells for
space. This is a reasonable assumption since accord-
ing to observations (Kyle et al., 1999) the volume
of extracellular space in tumours is typically in the
range 25-65% of the total volume of cells and hence
there is enough space for the migration of lympho-
cytes within a tumour. Also, tumour cells lack the
contact inhibition properties of normal cells and de-
stroy the extracellular matrix. This allows the lym-
phocytes to migrate into the tumour tissue faster
than in normal tissue, which has regular extracellu-
lar matrix. Therefore we do not explicitly include a
term for space competition between the tumour cells
and the lymphocytes and thus a logistic growth term
is, we believe, a good first modelling approximation
to the tumour growth kinetics.
In the presence of CTLs and antigen presenting
cells, the ODE governing the tumour growth dynam-
ics in conjunction with the interactions dictated by
the kinetic scheme in Fig. 1 is:
dT
dt
= −
mass action kinetics, according to Fig. 1︷ ︸︸ ︷
k+T ET +
(
k−T + kCT (1− p)
)
CT
−
mass action kinetics︷ ︸︸ ︷
kATA +
logistic growth︷ ︸︸ ︷
b1T (1− b2T ) (3)
where b1, b2, p, k±T , kCT and kA are positive param-
eters.
Antigen presenting cells
The antigen presenting cell population is represented
by two variables, distinguishing between those anti-
gen presenting cells that are associated with an in-
ternalized tumour cell and those that are not. The
former population is denoted by L (loaded cell pop-
ulation), whereas the latter is denoted by A.
As in the case of CTLs, the model incorporates
a source term modelling the underlying cell produc-
tion by the host immune system and a linear decay
(death) term. Combining these processes with the
kinetic scheme in Fig. 1, we get the following equa-
tion for the non-tumour-bearing population:
dA
dt
=
supply︷︸︸︷
s2 −
linear decay︷︸︸︷
d2A −
mass action kinetics︷ ︸︸ ︷
kATA+ kLL (4)
where the parameters s2 and d2 correspond to the
flow of antigen presenting cells into the tissue and
the decay constant due to cell death respectively.
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Table 1: Estimated kinetic rate constants.
Symbol Value Symbol Value Symbol Value
g 2.02× 107 cells b2 2.0× 10−9 cells−1 k−T 24 day−1
k+T 1.3× 10−7 day−1cells−1 kCT 7.2 day−1 p 0.9997
d1 0.0412 day−1 f 0.2988× 108 day−1cells b1 0.18 day−1
s1 1.36× 104 day−1cells kA 0.5× 10−6 day−1cells−1 kL 10.0 day−1
k+L 1.3× 10−7 day−1cells−1 k−L 24 day−1 kCA 7.2 day−1
k+E 1.3× 10−7 day−1cells−1 k−E 24 day−1 kCE 7.2 day−1
s2 1.36× 104 day−1cells d2 0.0412 day−1
The dynamics of the loaded cell population are
governed by the kinetic scheme in Fig. 1, and the
corresponding equation for L is:
dL
dt
= kATA− kLL− k+LLE + k−LCA (5)
Cell complexes
The dynamics of cell-complexes are governed by the
kinetics derived from Fig. 1. Therefore the equa-
tions for the complexes are given by:
dCT
dt
= k+T ET − (k−T + kCT )CT , (6)
dCA
dt
= k+LLE − (k−L + kCA)CA, (7)
dCE
dt
= k+EE
2 − (k−E + kCE )CE . (8)
Cells programmed for lysis
The time-dependent variables corresponding to the
tumour cells and APCs that have been programmed
for lysis are “slave variables” of the system and don’t
provide any feedback to the equations for the other
cell types. Hence, in the following we focus on the
system of equations (1)-(8).
2.2 Estimation of parameters
In order to carry out an analysis of the model by
numerical methods it is useful to estimate values for
the parameters obtained from experimental data and
work with a non-dimensionalized system of equa-
tions.
The murine B cell lymphoma (BCL1) is used as an
experimental model of tumour dormancy in mouse
(Siu et al., 1986; Uhr & Marches, 2001). It has
been demonstrated that CD8+ T-cells (CTLs) are
required for inducing and maintaining dormancy in
BCL1. In these experiments CD8+ T cells are en-
hanced with anti-Id antibodies into inducing dor-
mancy by secreting INF-γ. A description of the
growth kinetics of a BCL1 lymphoma in the spleen
of recipient mice, chimeric with respect to the Major
Histocompatibility Complex (Siu et al., 1986), was
provided by the model of Matzavinos et al. (2004).
The kinetic constants that correspond to the in-
teractions of CTLs with tumour cells in the model
developed in this paper have been obtained from
Matzavinos et al. (2004). The remaining of the ki-
netic constants have been chosen on the basis of
generic order of magnitude estimates. The latter
were obtained by comparison of the associated time
scales with those corresponding to the fitted kinetic
constants of Matzavinos et al. (2004). Table 1 shows
the values of the kinetic constants used in the numer-
ical simulations of the following section.
The system of equations (1)-(8) is closed by ap-
plying appropriate initial conditions. The initial cell
counts of effector and tumour cells are those used by
Matzavinos et al. (2004) and are given by:
E0 =
s1
d1
and T0 =
1
b2
. (9)
Under physiological conditions, in the absence of a
tumour and assuming that the Fas/FasL apoptotic
pathway is inactive, the steady-state value of E is
s1/d1 and therefore this is the value we have taken
for the initial cell count E0. Similarly, in the absence
of an immune response,the steady-state tumour cell
count is 1/b2 and this is what we take as the initial
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Figure 2: Evolution in time of (non-dimensionalized)
tumour cell counts under different initial numbers
of (a) antigen presenting cells and (b) cytotoxic T-
lymphocytes.
tumour cell count T0. It is assumed that there are no
cell complexes or tumour cell-loaded APCs initially.
Finally, the initial CTL to APC ratio is assumed to
be 1 : 10.3
The closed system has been non-dimensionalized
by choosing order-of-magnitude scales according to
the initial conditions, and the numerical results in
the next section are given in terms of the non-
dimensionalized system.
3Estimates of the CTL to APC ratio in the literature vary
from 10 : 1 to 1 : 30 (in tumour infiltrates).
3 Results
The non-dimensionalized system was solved nu-
merically under different experimental settings us-
ing the stiff solver of the XPP numerical package
(Ermentrout, 2002). A stiff solver is needed for solv-
ing numerically the ODE model developed in this
paper due to the wide range of parameter values in
Table 1.
The main focus of the numerical experiments was:
(a) to investigate the relative importance of CTLs
and antigen presenting cells on tumour dormancy
and tumour recurrence and (b) to quantify the ef-
fectiveness of different cancer vaccination protocols.
The vaccination protocols considered were based on
the administration of antigen presenting cell vaccines
(Banchereau & Palucka, 2005), and the effectiveness
of the latter was compared to that of an adoptive
(passive) immunotherapy approach based on the ad-
ministration of CTLs (Gattinoni et al., 2006). An
excellent review of the current cancer immunother-
apy approaches is given by Gilboa (2004).
Figures 2(a) and 2(b) show the results of a com-
putational experiment that quantifies how different
numbers of CTLs and antigen presenting cells affect
the time period between tumour regression and re-
currence. All parameter values for these simulations
were set according to Section 2.2. The initial condi-
tions for variables A in Fig. 2(a) and E in Fig. 2(b)
were varied in a biologically-relevant range around
the values adopted in Section 2.2.
For all parameter values investigated, in both Figs.
2(a) and 2(b), the tumour cell population intially
decreases in number before subsequently settling to
some stationary value for a finite period of time. For
visualization purposes, the transient decrease in the
number of tumour cells is not shown. The reduced
tumour bulk attained in the simulations after tu-
mour regression persists until the tumour recurs at
a time that depends on the initial CTL and antigen
presenting cell counts. As shown in Fig. 2(a), the
initial antigen presenting cell count correlates well
with the tumour dormancy period, and the model
suggests that elevated numbers of antigen presenting
cells result in significantly delaying tumour recur-
rence. These results also suggest a potential role for
antigen presenting cells as biological markers, indi-
cating high-risk time periods for tumour recurrence.
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Figure 3: (a) Effect of parameter kCE on the dor-
mancy period and the recurrence of the disease. (b)
Continuation of the non-dimensionalized solution for
variable T with respect to kCE .
Figure 2(b) shows an interesting, counter-intuitive
phenomenon. According to the model under inves-
tigation, elevated initial numbers of CTLs (as com-
pared to the base value in Section 2.2) result in a
reduced period of cancer dormancy and an early
recurrence of the disease. Moreover, relatively re-
duced initial numbers of CTLs result in a prolonged
dormancy period. This phenomenon should be at-
tributed to the cytotoxicity of activated lymphocytes
to each other (Fas/FasL interactions). Indeed, initial
conditions that are characterized by elevated num-
bers of CTLs result not only to tumour cell killing,
but also to CTL killing, enabling tumour cells to
escape cancer dormancy on a faster time scale.
These results offer a possible explanation for
a number of reported failures of CTL vaccine-
based therapeutic approaches to certain carcinomas
(see, for example, Zhang et al., 2007). The ra-
tionale of such approaches is based on the well-
documented correlation between melanoma patient
survival and tumour infiltrating lymphocyte (TIL)
counts (Weinberg, 2007). However, TIL popula-
tions are highly heterogeneous, including among
others CTLs (CD8+ cells), natural killer-like (NK-
like) cells and/or lymphokine activated killer (LAK)
cells, with different TIL subpopulations showing dif-
ferent degrees of sensitivity to Fas/FasL mediated
apoptosis. Hence, the reported correlation between
melanoma patient survival and TIL counts does not
contradict the results in this section, since the lat-
ter are related to CTLs that are responsive to the
Fas/FasL signalling pathway. Moreover, the dynam-
ics of the model under investigation are consistent
with well-documented tumour recurrence phenom-
ena, following the application of CTL-based vacci-
nation protocols (Zhang et al., 2007).
In addition to observing the effect of different cell
counts on the dormancy period, we also investigated
how the latter is affected by the time scale on which
lymphocytes detect and bind to tumour cells, as well
as by the cytotoxicity of CTLs to each other. Fig-
ure 3(a) shows the evolution in time of the tumour
cell population for three different values of the ki-
netic parameter kCE that measures the rate by which
CTLs inactivate/kill each other through Fas/FasL
interactions. Interestingly enough, reducing param-
eter kCE leads to early tumour recurrence associated
with a reduced tumour bulk. In contrast, increasing
kCE results in prolonging the dormancy period and
delaying the recurrunce of the disease. However, the
model predicts that increasing kCE also results in an
enlarged tumour bulk after recurrence. Figure 3(b)
shows a continuation of the (non-dimensionalized)
solution for variable T with respect to parameter
kCE .
Interesingly enough, reducing parameter kCE be-
low the value of 1 day−1 does not result in complete
eradication of the tumour mass, as one would ex-
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Figure 4: Emergence of periodic recurrences for small values of parameter kCE
pect by extrapolation of the data in Fig. 3(b). In-
stead, in this parameter regime, the evolution of the
disease is characterized by periodic recurrences; a
phenomenon that frequently appears in the context
of general immune-pathogen interactions (Wodarz,
2007) and has also been documented in the specific
case of tumour-immune interactions (Kirschner &
Panetta, 1998; Kuznetsov et al., 1994; Matzavinos
& Chaplain, 2004). Figure 4 shows the dependence
of the emerging oscillatory solutions on parameter
kCE . The model predicts that, although the first re-
currence of the disease is independent of the value
of kCE , subsequent recurrences will strongly depend
on the sensitivity of the effector cells to Fas/FasL
mediated apoptosis. Numerical continuation of the
system with the XPP implementation of the AUTO
continuation software (Ermentrout, 2002) confirmed
that these oscillatory dynamics emerge through a
Hopf bifurcation with respect to parameter kCE .
Figure 5(a) shows the evolution in time of the tu-
mour cell population for four different values of the
kinetic parameter k+T , which determines the time
scale of CTL-binding to tumour cells. As can be
seen, elevated values for k+T result in both a pro-
longed dormancy period and a reduced tumour bulk
after recurrence of the disease. This result indicates
the importance of identifying immunodominant tu-
mour peptides in the development of cancer vaccines
(Raitakari et al., 2003) and suggests a cellular pro-
cess, the facilitation of which would enhance the ef-
fectiveness of the vaccine.
In addition to vaccine effectiveness, we investi-
gated computationally the effectiveness of different
vaccine administration protocols. Figure 5(b) shows
how the time period elapsed before recurrence of
the disease depends on the number of monthly im-
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Figure 5: (a) Effect of parameter k+T on the dormancy period and the recurrence of the disease, (b) Plot of
the tumour dormancy time period versus the number of immunizations for two different cancer vaccination
protocols.
munizations under two different vaccination strate-
gies. As can be seen active vaccination with tumour-
antigen pulsed APCs is associated with a positive
correlation between the number of immunizations
and the tumour dormancy period, and it is gen-
erally more effective than adoptive immunotherapy
protocols. In contrast, the adoptive (passive) imn-
munotherapy protocol simulated (based on CTL vac-
cines) fails to mount an effective immune response
even in the case of a significant number of repeated
immunizations.
4 Discussion
In this paper we have developed a mathematical
model to describe the growth dynamics of an im-
munogenic tumour in the presence of an active im-
mune response. In particular, we focused attention
upon the interaction of tumour cells with CD8+ cy-
totoxic T-lymphocytes and professional antigen pre-
senting cells in a relatively small, multicellular tu-
mour, without central necrosis and at some stage
prior to tumour-induced angiogenesis (Weinberg,
2007). Following the approach of Matzavinos et al.
(2004) and Matzavinos & Chaplain (2004), the cyto-
toxic T-lymphocytes were assumed to interact with
the tumour cells in such a way that lymphocyte-
tumour cell complexes were formed. These com-
plexes resulted in either the death of the tumour cells
(the normal situation) or the inactivation (some-
times even the death) of the lymphocytes.
The model developed in this paper extends the
work of Chaplain & Matzavinos (2006) by investi-
gating the role of antigen presentation and costim-
ulatory signaling pathways on the well-documented
phenomena of cancer dormancy and recurrence. In
particular, in the formulation of the model we con-
sidered a generic type of professional antigen pre-
senting cell that was assumed to internalize tumour
cells through either phagocytosis or endocytosis and
display selected tumour antigenic peptides to the ef-
fector cells, i.e., the cytotoxic T-lymphocytes (Abbas
et al., 2007).
The dynamics of the model were investigated by
means of numerical simulations, and a number of in-
teresting, counter-intuitive phenomena were discov-
ered. It was demonstrated that, under the assump-
tions of the model, adoptive immunotherapy proto-
cols have the potential to promote tumour growth
instead of inhibiting it. These results are consistent
with well-documented tumour recurrence phenom-
ena following the application of CTL-based vaccina-
tion protocols (Zhang et al., 2007). In contrast, ac-
tive vaccination with tumour-antigen pulsed APCs
(Banchereau & Palucka, 2005) was shown to be gen-
Joshi et al. – On immunotherapies and cancer vaccination protocols 10
erally more effective than adoptive immunotherapy
protocols in inhibiting tumour growth and recur-
rence in the model under investigation.
The numerical predictions of our model offer a
possible explanation for the uncontrolled behaviour
of a number of lymphocyte vaccine-based therapeu-
tic approaches to certain carcinomas, and our mod-
elling and analysis offers the potential for quantita-
tive analysis of mechanisms of tumour-cell-host-cell
interactions and for the optimization of immunother-
apy and genetically engineered anti-tumour vaccines.
Acknowledgements
The authors would like to thank Avner Friedman for
advice and encouragement. This material is based
upon work supported by the National Science Foun-
dation under agreement No. 0635561.
References
Abbas, A., Lichtman, A. & Pillai, S. (2007), Cellu-
lar and Molecular Immunology, 6th edn, Saun-
ders/Elsevier.
Ambrosi, D., Bellomo, N. & Preziosi, L. (2002),
‘Modelling tumor progression, heterogeneity,
and immune competition’, J. Theor. Medicine
4, 51–65.
Arlotti, L., Gamba, A. & Lachowicz, M. (2002), ‘A
kinetic model of tumor/immune system cellular
interactions’, J. Theor. Medicine 4, 39–50.
Banchereau, J. & Palucka, A. (2005), ‘Dendritic cells
as therapeutic vaccines against cancer’, Nature
Reviews Immunology 5, 296–306.
Bellomo, N. & Preziosi, L. (2000), ‘Modelling and
mathematical problems related to tumor evolu-
tion and its interaction with the immune sys-
tem’, Math. Comp. Modelling 32, 413–452.
Bellomo, N., Bellouquid, A. & De Angelis, E. (2003),
‘The modelling of the immune competition by
generalized kinetic (Boltzmann) models: Re-
view and research perspectives’, Math. Comp.
Modelling 37, 65–86.
Bellomo, N., Firmani, B. & Guerri, L. (1999), ‘Bi-
furcation analysis for a nonlinear system of
integro-differential equations modelling tumor-
immune cells competition’, Appl. Math. Letters
12, 39–44.
Chaplain, M. & Matzavinos, A. (2006), Mathe-
matical modelling of spatio-temporal phenom-
ena in tumour immunology, in A. Friedman,
ed., ‘Tutorials in Mathematical Biosciences III:
Cell Cycle, Proliferation, and Cancer’, Vol.
1872 of Lecture Notes in Mathematics, Springer,
pp. 131–183.
Chaplain, M., Kuznetsov, V., James, Z. &
Stepanova, L. (1998), Spatio-temporal dynam-
ics of the immune system response to cancer,
in M. A. Horn, G. Simonett & G. Webb, eds,
‘Mathematical Models in Medical and Health
Sciences’, Vanderbilt University Press, pp. 1–
20.
De Angelis, E., Delitala, M., Marasco, A. & Romano,
A. (2003), ‘Bifurcation analysis for a mean field
modelling of tumor and immune system compe-
tition’, Math. Comp. Modelling 37, 1131–1142.
Durand, R. & Sutherland, R. (1984), ‘Growth and
cellular characteristics of multicell spheroids’,
Recent Results in Cancer Research 95, 24–49.
Ermentrout, G. (2002), Simulating, Analyzing, and
Animating Dynamical Systems: A Guide to
XPPAUT for Researchers and Students, Vol. 14
of Software, Environments, and Tools, SIAM.
Forys´, U. (2002), ‘Marchuk’s model of immune
system dynamics with application to tumour
growth’, J. Theor. Medicine 4, 85–93.
Gatenby, R. (1995), ‘Models of tumor-host intearca-
tion as competing populations: Implications for
tumor biology and treatment’, J. theor. Biol.
176, 447–455.
Gatenby, R. (1996), ‘Application of competition the-
ory to tumour growth: Implications for tumour
biology and treatment’, European Journal of
Cancer 32A, 722–726.
Joshi et al. – On immunotherapies and cancer vaccination protocols 11
Gattinoni, L., Jr., D. P., Rosenberg, S. & Restifo,
N. (2006), ‘Adoptive immunotherapy for can-
cer: building on success’, Nature Reviews Im-
munology 6, 383–393.
Gilboa, E. (2004), ‘The promise of cancer vaccines’,
Nature Reviews Cancer 4, 401–411.
Kelly, C., Leek, R., Byrne, H., Cox, S., Harris, A. &
Lewis, C. (2002), ‘Modelling macrophage infil-
tration into avascular tumours’, J. Theor. Med.
4, 21–38.
Kirschner, D. & Panetta, J. (1998), ‘Modeling im-
munotherapy of the tumor immune interac-
tion’, J. Math. Biol. 37, 235–252.
Kuznetsov, V., Makalkin, I., Taylor, M. & Perelson,
A. (1994), ‘Nonlinear dynamics of immunogenic
tumours: Parameter estimation and global bi-
furcation analysis’, Bull. Math. Biol. 56, 295–
321.
Kyle, A., Chan, C. & Minchinton, A. (1999), ‘Char-
acterization of three-dimensional tissue cultures
using electrical impedance spectroscopy’, Bio-
phys J. 76(5), 2640–2648.
Marsden, V. & Strasser, A. (2003), ‘Control of
apoptosis in the immune system: Bcl-2, BH3-
only proteins and more’, Annu. Rev. Immunol.
21, 71–105.
Matzavinos, A. & Chaplain, M. (2004), ‘Travelling-
wave analysis of a model of the immune re-
sponse to cancer’, C.R. Biologies 327, 995–
1008.
Matzavinos, A., Chaplain, M. & Kuznetsov, V.
(2004), ‘Mathematical modelling of the spatio-
temporal response of cytotoxic T-lymphocytes
to a solid tumour’, Mathematical Medicine and
Biology: A Journal of the IMA 21, 1–34.
O’Connell, J., Bennett, M., O’Sullivan, G., Collins,
J. & Shanahan, F. (1999), ‘The Fas counter-
attack: cancer as a site of immune privilege’,
Immunol. Today 20(1), 46–50.
Owen, M. & Sherratt, J. (1997), ‘Pattern forma-
tion and spatio-temporal irregularity in a model
for macrophage-tumour interactions’, J. Theor.
Biol. 189, 63–80.
Owen, M. & Sherratt, J. (1998), ‘Modelling the
macrophage invasion of tumours: Effects on
growth and composition’, IMA J. Math. Appl.
Med. Biol. 15, 165–185.
Owen, M. & Sherratt, J. (1999), ‘Mathematical
modelling of macrophage dynamics in tumours’,
Math. Models Meth. Appl. Sci. 9, 513–539.
Parmiani, G. & Lotze, M., eds (2002), Tumor Im-
munology: Molecularly Defined Antigens and
Clinical Applications, Vol. 1 of Tumor Im-
munology and Immunotherapy Series, Taylor &
Francis.
Prigogine, I. & Lefever, R. (1980), ‘Stability prob-
lems in cancer growth and nucleation’, Comp.
Biochem. Physiol. 67, 389–393.
Raitakari, M., Brown, R., Gibson, J. & Joshua, D.
(2003), ‘T cells in myeloma’, Hematological On-
cology 21(1), 33–42.
Ries, L., Melbert, D., Krapcho, M., Mari-
otto, A., Miller, B., Feuer, E., Clegg, L.,
Horner, M., Howlader, N., Eisner, M., Re-
ichman, M. & Edwards, B., eds (2007),
SEER Cancer Statistics Review, 1975-2004,
National Cancer Institute. Bethesda, MD.
http://seer.cancer.gov/csr/1975 2004/.
Sherratt, J., Perumpanani, A. & Owen, M. (1999),
Pattern formation in cancer, in M. Chaplain,
G. Singh & J. McLachlan, eds, ‘On Growth and
Form: Spatio-temporal Pattern Formation in
Biology’, John Wiley & Sons Ltd.
Siu, H., Vitetta, E., May, R. & Uhr, J. (1986), ‘Tu-
mour dormancy. regression of BCL tumour and
induction of a dormant tumour state in mice
chimeric at the major histocompatibility com-
plex’, J. Immunol. 137, 1376–1382.
Szyman´ska, Z. (2003), ‘Analysis of immunother-
apy models in the context of cancer dynamics’,
Appl. Math. Comp. Sci. 13, 407–418.
Joshi et al. – On immunotherapies and cancer vaccination protocols 12
Uhr, J. & Marches, R. (2001), ‘Dormancy in a model
of murine B cell lymphoma’, Seminars in Can-
cer Biology 11, 277–283.
Webb, S., Sherratt, J. & Fish, R. (2002), ‘Cells
behaving badly: a theoretical model for
the Fas/FasL system in tumour immunology’,
Mathematical Biosciences 179, 113–129.
Weinberg, R. (2007), The Biology of Cancer, Gar-
land Science, Taylor and Francis Group.
Wodarz, D. (2007), Killer Cell Dynamics: Mathe-
matical and Computational Approaches to Im-
munology, Vol. 32 of Interdisciplinary Applied
Mathematics, Springer.
Zhang, X., Moche, J., Farber, D. & Strome, S.
(2007), ‘Vaccine-based approaches to squamous
cell carcinoma of the head and neck’, Oral Dis-
eases 13, 17–22.
